8-KEarnings & ResultsExhibits & Filings

THERMO FISHER SCIENTIFIC INC. 8-K Report, Financial Results (Oct 26, 2005)

Filed October 26, 2005For Securities:TMO

Summary

Thermo Fisher Scientific Inc. (TMO) announced its third-quarter 2005 financial results, showcasing robust top-line growth with revenues increasing by 25% year-over-year to $679 million. This growth was significantly fueled by strategic acquisitions, contributing approximately 20% of the increase, and bolstered by new product introductions, particularly in the mass spectrometry portfolio. While GAAP diluted EPS saw a decrease to $0.35 from $0.65 (which included a significant gain from discontinued operations in the prior year), adjusted diluted EPS demonstrated strong growth, rising 25% to $0.40. The company also reported an increase in adjusted operating income of 41% and an expansion of adjusted operating margin by 160 basis points to 14.7%, indicating improving operational efficiency despite integration costs from recent acquisitions. Key strategic moves during the quarter included the divestiture of the Point of Care diagnostics business, deemed not a strategic fit for the long term. Looking ahead, Thermo Fisher raised the lower end of its full-year adjusted EPS guidance, now expecting between $1.51 and $1.54, representing 21-23% growth over the previous year. Full-year revenue growth is projected at 18-19%, reaching an estimated $2.61 to $2.63 billion. Investors should note the significant impact of acquisitions on revenue and the management's focus on adjusted non-GAAP metrics for performance evaluation, which exclude acquisition-related intangible asset amortization and restructuring costs.

Key Highlights

  • 1Q3 2005 revenues grew 25% to $679 million, driven by 20% contribution from acquisitions and new product development.
  • 2Adjusted diluted EPS increased 25% to $0.40, demonstrating strong underlying profitability.
  • 3Adjusted operating income surged 41%, and adjusted operating margin improved by 160 basis points to 14.7%.
  • 4The company enhanced its mass spectrometry portfolio through new product launches and the acquisition of Ionalytics Corporation.
  • 5Thermo Fisher divested its Point of Care diagnostics business, aligning its portfolio with long-term strategic goals.
  • 6Full-year 2005 revenue growth is projected at 18-19%, with adjusted EPS guidance raised to $1.51-$1.54.
  • 7Significant increase in acquisition-related intangible assets and goodwill on the balance sheet, reflecting strategic M&A activity.

Frequently Asked Questions

Revenue growth of 25% in Q3 2005 was primarily driven by strategic acquisitions, which contributed approximately 20% of the increase, and by new product developments, particularly within the mass spectrometry portfolio. Organic growth and currency translation had a minimal impact.

While GAAP diluted EPS decreased to $0.35 from $0.65 (which included a large gain from discontinued operations in the prior year), adjusted diluted EPS grew 25% to $0.40. Adjusted operating income also saw a substantial increase of 41%, and adjusted operating margin expanded by 160 basis points to 14.7%, indicating improved operational performance excluding acquisition-related charges and restructuring costs.

Thermo Fisher divested its Point of Care diagnostics business, as it was not considered a strategic fit for the long term. The company also continued to integrate recent acquisitions, such as Kendro, and strategically invested in R&D for new product launches, especially in mass spectrometry.

Thermo Fisher raised its full-year guidance, now expecting revenues to increase by 18-19% to approximately $2.61-$2.63 billion. Adjusted EPS is projected to be between $1.51 and $1.54, representing a 21-23% increase over the previous year.